Correlation Engine 2.0
Clear Search sequence regions

  • adult (1)
  • allele (1)
  • bevacizumab (4)
  • direct (1)
  • dna (1)
  • female (1)
  • free (1)
  • gene (5)
  • homeostasis (1)
  • humans (1)
  • male (1)
  • out patients (1)
  • over (1)
  • patients (5)
  • patients reaction (1)
  • protein human (1)
  • regions (1)
  • risk factors (1)
  • VEGF (9)
  • vegfa protein, human (1)
  • Sizes of these terms reflect their relevance to your search.

    Among the possible genetic contributors to cancer-related venous thromboembolism (VTE), vascular endothelial growth factor (VEGFA) could play an important role, as an imbalance of the VEGFA system (either disease-related or drug-induced) may result in a disturbance of vascular homeostasis. Thus, this study was designed to investigate the predictive role of eight different VEGFA gene promoter single nucleotide polymorphisms (SNPs) for a first VTE episode in cancer out-patients undergoing chemotherapy. To this purpose, VEGFA gene promoter polymorphisms were analysed in 297 cancer patients using polymerase chain reaction amplification and direct DNA sequencing analysis. One hundred forty unrelated healthy subjects from the same geographical area were also analysed in order to evaluate and compare genotype/haplotype frequencies in our ethnicity. VTE occurred in 26 (9%) of cancer patients with a median time-to-event of 3.4 months. Association analyses showed that -1154G/A polymorphism was significantly associated with the risk of chemotherapy-triggered VTE, with the A allele exerting a protective role both in the overall population (hazard ratio [HR]: 0.21; 95% confidence interval [CI]: 0.07-0.58) or in bevacizumab-treated metastatic patients (HR: 0.09, 95%CI: 0.01-0.86) in whom VEGFA -1154AA genotype also conferred a reduced risk of early progression (HR: 0.58, 95%CI: 0.34-0.98). These results suggest that VEGFA may represent a candidate gene contributing to VTE development in chemotherapy treated cancer patients and that -1154G/A SNP might provide useful clinical information on the efficacy and toxicity of bevacizumab in metastatic patients. Validation studies are needed for translation into clinical practice.


    Patrizia Ferroni, Raffaele Palmirotta, Silvia Riondino, Maria Laura De Marchis, Antonella Nardecchia, Vincenzo Formica, Fiorella Guadagni, Mario Roselli. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. Thrombosis and haemostasis. 2016 Jan;115(1):143-51

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 26336029

    View Full Text